SCHEMBL1703311

SCHEMBL1703311

Cn1cc(Nc2ncc(Cl)c(Nc3ccccc3C3(O)CCC3)n2)cn1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 6/20 0.64
▸ CDK2 P24941 3/20 0.64
▸ CDC7 O00311 2/20 0.64
▸ DAPK3 O43293 2/20 0.64
▸ ROCK2 O75116 2/20 0.64
▸ PRKD3 O94806 2/20 0.64
▸ MAP4K4 O95819 2/20 0.64
▸ PAK4 O96013 2/20 0.64
▸ PIM1 P11309 2/20 0.64
▸ PRKACA P17612 2/20 0.64
▸ SYK P43405 2/20 0.64
▸ CSNK1A1 P48729 2/20 0.64
▸ CLK2 P49760 2/20 0.64
▸ GSK3A P49840 2/20 0.64
▸ GSK3B P49841 2/20 0.64
▸ CDK7 P50613 2/20 0.64
▸ CDK9 P50750 2/20 0.64
▸ PRKX P51817 2/20 0.64
▸ MAP4K2 Q12851 2/20 0.64
▸ STK3 Q13188 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1703985 0.92 CDK9 (0.61) JAK2CDK2CDC7DAPK3ROCK2
SCHEMBL1703336 0.88 ALK (0.67) JAK2CDK2CDC7DAPK3ROCK2
SCHEMBL1703580 0.86 KDR (0.66) JAK2CDK2CDC7DAPK3ROCK2
SCHEMBL1703586 0.80 ALK (0.69) JAK2CDK2CDC7DAPK3ROCK2
SCHEMBL1703321 0.79 ALK (0.67) JAK2CDK2CDC7DAPK3ROCK2
SCHEMBL1703165 0.79 CDK2 (0.38) JAK2CDK2CDC7DAPK3ROCK2
SCHEMBL2123417 0.77 ALK (0.67) JAK2CDK2CDC7DAPK3ROCK2
SCHEMBL1703043 0.76 KDR (0.65) JAK2CDK2CDC7DAPK3ROCK2
SCHEMBL2127160 0.75 JAK2 (0.65) JAK2CDK2CDC7DAPK3ROCK2
SCHEMBL2125776 0.74 JAK2 (0.63) JAK2CDK2CDC7DAPK3ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440548-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS Abbott Laboratories (US) 2012-04-18 — — EP claimed
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2010-12-16 — — US claimed
WO-2010144468-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-12-16 — — WO claimed
US-8426408-B2 Pyrimidine inhibitors of kinases ABBVIE INC. (US) 2013-04-23 — — US disclosed
EP-2440548-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS Abbott Laboratories (US) 2012-04-18 — — EP disclosed
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2010-12-16 — — US disclosed
WO-2010144468-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES AURKA, AURKC, AURKB JAK2 256/4885CDK2 13/4885CDC7 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback